GREENWICH, Conn.--(BUSINESS WIRE)--Aptuit, Inc. announced today that it has secured its first integrated drug delivery contract from Danube Pharmaceuticals. Aptuit will provide the company with a full range of drug development services and employ five of its global facilities to develop and manufacture Danube’s investigational compound in support of upcoming Phase II clinical trials. This project will include a wide range of Aptuit’s services including: API process development, cGMP API delivery, clinical manufacture, analytical services, clinical packaging and labeling, and Qualified Person (QP) release.
